Facebook
Twitter
LinkedIn
Forward
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
In adolescents and adults, the co-occurrence of eating disorders and overweight or obesity is continuing to increase.
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss.
|
Individual patient response to nutritional therapies varies widely.
|
The AAP has comprehensively updated their recommendations regarding the disease of obesity in childhood. The incidence of obesity in childhood has not improved.
|
This session will review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
The body mass index (BMI) is the most commonly used screening tool for obesity. However, the BMI is a population-based tool with several limitations when applied to individuals.
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|
Join Dr. Carolynn Francavilla and Stephanie Burke, both level 1 CrossFit Coaches, in this session where we look past BMI and see the inner athlete in everyone.
|